A double-blind, placebo-controlled cross-over study to assess the efficacy of topical calcipotriol (Psorcutan®-ointment containing 0.05 µg/g calcipotriol) to improve wound healing in dystrophic epidermolysis bullosa (DEB).
Phase of Trial: Phase II
Latest Information Update: 12 Oct 2016
At a glance
- Drugs Calcipotriol (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
- 12 Oct 2016 New trial record